CureVac (NASDAQ:CVAC – Get Free Report) and Genmab A/S (NASDAQ:GMAB – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.
Profitability
This table compares CureVac and Genmab A/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CureVac | 199.92% | -23.03% | -19.09% |
| Genmab A/S | 16.97% | 13.67% | 6.42% |
Volatility and Risk
CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for CureVac and Genmab A/S, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CureVac | 1 | 0 | 0 | 0 | 1.00 |
| Genmab A/S | 0 | 1 | 10 | 1 | 3.00 |
Genmab A/S has a consensus target price of $53.50, suggesting a potential upside of 5.90%. Given Genmab A/S’s stronger consensus rating and higher possible upside, analysts plainly believe Genmab A/S is more favorable than CureVac.
Earnings and Valuation
This table compares CureVac and Genmab A/S”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CureVac | $70.74 million | 14.78 | $175.50 million | $0.72 | 6.47 |
| Genmab A/S | $3.72 billion | 8.48 | $963.00 million | $1.17 | 43.18 |
Genmab A/S has higher revenue and earnings than CureVac. CureVac is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
17.3% of CureVac shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 2.1% of CureVac shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Genmab A/S beats CureVac on 10 of the 15 factors compared between the two stocks.
About CureVac
CureVac is a biotechnology company founded in 2000 and headquartered in Tübingen, Germany. It focuses on messenger RNA (mRNA) technology, which uses genetic instructions to prompt cells to produce proteins that may help prevent or treat disease. The company has developed mRNA-based vaccine and therapeutic candidates for infectious diseases and cancer. Its programs have included COVID-19 vaccines and oncology research, and it has worked with pharmaceutical partners, including GSK, on mRNA vaccine development.
About Genmab A/S
Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
